Alder Biopharmaceuticals
ALDR
ALDR was delisted on the 21st of October, 2019.
145 hedge funds and large institutions have $1.11B invested in Alder Biopharmaceuticals in 2016 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 66 increasing their positions, 37 reducing their positions, and 30 closing their positions.
333% more call options, than puts
Call options by funds: $2.78M | Put options by funds: $642K
78% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 37
0.99% more ownership
Funds ownership: 105.38% → 106.38% (+0.99%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
2% less capital inflows, than outflows
Capital inflows: $139M | Capital outflows: $142M
9% less funds holding
Funds holding: 159 → 145 (-14)
43% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 30
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PFM Health Sciences
San Francisco,
California
|
+$23.6M |
| 2 |
Janus Henderson Investors US
Denver,
Colorado
|
+$9.6M |
| 3 |
Clough Capital Partners
Boston,
Massachusetts
|
+$7.65M |
| 4 |
BlackRock Fund Advisors
San Francisco,
California
|
+$7.24M |
| 5 |
State Street
Boston,
Massachusetts
|
+$6.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Senator Investment Group
New York
|
-$32.8M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$20.8M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$12.2M |
| 4 |
Asset Management One
Tokyo,
Japan
|
-$9.7M |
| 5 |
Driehaus Capital Management
Chicago,
Illinois
|
-$7.63M |
ALDR Hedge Fund Activity: Q4 2016 in Review
145 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Alder Biopharmaceuticals (ALDR) for Q4 2016, worth a combined $1.11B — down 36% from $1.74B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of ALDR and 17 opened new positions — a net loss of 13 holders — while 37 trimmed existing stakes and 66 added.
The largest buyer was PFM Health Sciences, adding an estimated $23.6M. The largest seller was Senator Investment Group, exiting entirely with an estimated $32.8M sold.
- 145 institutional investors held Alder Biopharmaceuticals (ALDR) as of Q4 2016, down from 159 in Q3 2016.
- Funds reported $1.11B of Alder Biopharmaceuticals stock for Q4 2016, down 36% quarter-over-quarter.
- 17 funds opened new Alder Biopharmaceuticals positions in Q4 2016 and 30 closed out, a net change of -13 holders.
- The largest Alder Biopharmaceuticals buyer in Q4 2016 was PFM Health Sciences, an estimated $23.6M added.
- The largest Alder Biopharmaceuticals seller in Q4 2016 was Senator Investment Group, an estimated $32.8M sold.
Based on aggregated 13F filings for Q4 2016.